Antonio Urso

Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs

Chronic Lymphocytic Leukemia: Prognostic/Predictive Factors in the Era of Novel Drugs

Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study

Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi

Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency

First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era

Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first line ibrutinib: a nationwide registry study from the Italian Medicines Agency

First-line Treatment of the Older Patients with CLL: A New Approach in the Chemo-free Era

Spontaneously reversible adrenal nodules in primary diffuse large B-cell testicular lymphoma mimicking an extranodal involvement: A case report

In chronic lymphocytic leukaemia, <i>SLAMF1</i> deregulation is associated with genomic complexity and independently predicts a worse outcome

Response to ibrutinib of a refractory IgA lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation

In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics

Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemia

In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI

An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and <i>TP53</i> disruption as predictors of outcome and chemorefractoriness

AN EXTENSIVE MOLECULAR CYTOGENETIC CHARACTERIZATION IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA IDENTIFIES KARYOTYPE ABERRATIONS AND TP53 DISRUPTION AS PREDICTORS OF OUTCOME AND CHEMOREFRACTORINESS

Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations

Erratum to: Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations